Shopping Cart
Remove All
Your shopping cart is currently empty
Canakinumab (ACZ885) is a recombinant human IL-1β-targeting monoclonal antibody that inhibits human and chorioallantoic monkey IL-1β with IC50 values of 43.6 and 40.8 pM, respectively. It exhibits anti-inflammatory activity by neutralizing IL-1β signaling, and it has been used for the treatment of gout and coronary artery disease.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $179 | In Stock | In Stock | |
| 5 mg | $579 | In Stock | In Stock | |
| 10 mg | $826 | In Stock | In Stock | |
| 25 mg | $1,220 | - | In Stock | |
| 50 mg | $1,650 | - | In Stock |
| Description | Canakinumab (ACZ885) is a recombinant human IL-1β-targeting monoclonal antibody that inhibits human and chorioallantoic monkey IL-1β with IC50 values of 43.6 and 40.8 pM, respectively. It exhibits anti-inflammatory activity by neutralizing IL-1β signaling, and it has been used for the treatment of gout and coronary artery disease. |
| Targets&IC50 | IL-1β:40.8 pM (marmoset), IL-1β:43.6 pM (human) |
| In vitro | Dose-dependently, Canakinumab (0-7 nM) represses IL-6 production in marmoset peripheral blood mononuclear cells, demonstrating IC50s of 43.6 and 40.8 pM for human and marmoset IL-1β, respectively[2]. Effectively, Canakinumab competes with IL-1RI and IL-1RII for binding to IL-1b[2]. |
| Synonyms | Ilaris, ACZ 885 |
| Molecular Weight | 145.18 kDa |
| Cas No. | 914613-48-2 |
| Color | Transparent |
| Appearance | Liquid |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.